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Pluripotent stem cells (PSCs) hold, through the capacity to differentiate into virtually all
body cell types, unprecedented promise for human and animal medicine. PSCs are
naturally found in the early embryo, and in rodents and humans they can be robustly
harvested and grown in culture in the form of embryonic stem cells (ESCs); however,
the availability of ESCs from horses is limited. ES-like cells named induced pluripotent
stem cells (iPSCs) can be derived in vitro by transcription factor-mediated reprogramming
of adult cells. As such, iPSCs can be generated in a patient-specific manner providing
unmatched potential for tissue transplantation and in vitro disease modeling. In humans,
clinical trials using iPSC-derived cells are already taking place and the use of in vitro iPSC
models has identified novel mechanisms of disease and therapeutic targets. Although
to a more limited extent, iPSCs have also been generated from horses, a species in
which, after humans, these cells are likely to hold the greatest potential in regenerative
medicine. Before a clinical use can be envisioned, however, significant challenges will
need to be addressed in relation to the robust derivation, long-term culture, differentiation,
and clinical safety of equine iPSCs. Toward this objective, recent studies have reported
significant improvement in culture conditions and the successful derivation for the first time
of functional cell types from equine iPSCs. Given the wide range of exciting applications
they could have, it is hoped future research will make the biomedical promise of iPSCs a
reality not only for humans but also horses.
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Stem cells are defined based on their capacity for self-renewal and the ability to differentiate into
specialized cell types (potency). In contrast to multipotent stem cells (including mesenchymal stem
cells or MSCs), pluripotent stem cells (PSCs) are intrinsically able to self-renew indefinitely and to
give rise to virtually all cell types in the body, features that provide distinct advantages in relation
to regenerative medicine applications and for which PSCs have been the subject of intense research
over the past 30 years. Although pluripotent cells are found naturally only in the early mammalian
embryo, pluripotency can be captured in vitro in the form of embryonic stem cells (ESCs) generated
from cultures of the inner cell mass, the forerunner of the embryo proper in the very early conceptus
(1, 2). ESC lines that maintain their pluripotency in vivo, i.e., are able to give raise to differentiated
teratomas when injected into immunodeficient mice, have been robustly derived from rodents and
humans but not, to this date, from domestic species, including the horse. This is partly attributed to
the relative lack of knowledge of early embryo development in domestic species, which precludes
the use of optimal conditions to stably maintain embryonic cells in an undifferentiated state.
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Nonetheless, cultures of equine embryonic cells that lack pluripo-
tency in vivo have been established by several groups (3, 4) and
their potential in relation to veterinary regenerative medicine is
being investigated (5, 6).
GENERATION AND CHARACTERIZATION
OF EQUINE iPSCs
In 2006, Shinya Yamanaka’s group in Japan showed that cells
equivalent to ESCs, named induced pluripotent stem cells (iPSCs),
could be generated in culture from murine fibroblasts by simply
inducing the expression of four genes, namely the pluripotency-
associated transcription factors, Oct4, Sox2, Klf4, and Myc (7).
This seminal discovery was followed shortly after by the suc-
cessful generation of iPSCs from humans (8) and opened the
way to the derivation, without the need to use embryos, of
patient-specific PSCs that could be used for autologous tissue
transplantation, thus, providing a clear advantage over ESCs. For
his discoveries, Yamanaka was awarded the 2012 Nobel Prize in
Medicine.
The first reports on mouse and human iPSCs in 2006–2007
led to a deluge of studies aiming to identify cell sources and
gene expression systems that would allow efficient reprogram-
ming using minimal genetic modification of the resulting iPSCs,
a crucial requisite for an eventual clinical application of these
cells. Studies soon extended to domestic animal species where
iPSC technology was seen as a highly promising alternative to
ESCs (9–12). In the horse, the prospect of a new source of stem
cells for clinical use led to the first report on equine iPSCs in
2011 (13) followed by several additional publications over the
following 3 years (14–17). The cells generated in these studies
displayed, at various levels, features of equine embryonic cells
and iPSCs from mice and humans (Table 1), including mor-
phology, re-activated expression of molecular markers of pluripo-
tency and the ability, in some studies, to generate differentiated
teratomas in vivo, which is to-date the most stringent proof of
pluripotency in the horse. Equine iPSCs were generated from
fetal or adult fibroblasts and, in one of the studies, keratinocytes
(Table 1); consistent with reports in humans (18), equine ker-
atinocytes were relatively more amenable to reprogramming than
fibroblasts and, in addition, once reprogrammed they had higher
developmental plasticity than fibroblast-derived iPSCs as indi-
cated by their ability to produce differentiated tissues in vivo as
diverse as neurons, cartilage, muscle, lung epithelium, and gastric
epithelium (16).
Reprogramming of equine cells was achieved in most stud-
ies by using viral expression vectors that mediate the integra-
tion of the reprogramming gene sequences (Oct4, Sox2, Klf4,
and Myc) into the cell genome, therefore, making the repro-
grammed cells not apt for clinical use. Only one study (13) used
a non-integrating expression vector (piggyBac transposon) to
reprogram equine cells, although this was done at the cost of
reduced robustness of the resulting iPSCs, as switching off the
TABLE 1 | Characteristics of reported equine iPSCs.
Nagy et al. (13) Breton et al. (15) Khodadadi et al. (14) Sharma et al. (16) Whitworth et al. (17)
Reprogramming cell
source
Dermal fibroblasts,
55-day-old fetus
Dermal fibroblasts,
5-month-old foal and
2-year-old gelding
Fibroblasts, adult horse Keratinocytes,
5-month-old filly
Dermal Fibroblasts,
adult mare
Reprogramming
system
piggyBac transposon
containing murine Oct4,
Sox2, Klf4 and Myc,
tetracycline-driven
MMLV vector expressing
murine Oct4, Sox2, Klf4 and
Myc,
MMLV vector
expressing human
OCT4, SOX2, and
KLF4
MMLV vector
expressing murine
Oct4, Sox2, Klf4 and
Myc
Lentivirus vector
expressing human
OCT4, SOX2, KLF4,
and MYC
Culture conditions DMEM high glucose, FBS,
LIF, bFGF, CHIR99021,
PD0325901, A83-01,
Thiazovivin, SB431542
Knock-out (KO) DMEM, KO
serum replacement, LIF,
bFGF
α-MEM, FBS, ITS, LIF,
bFGF, EGF
Equine fetal fibroblast-
conditioned media (KO
DMEM, KO serum
replacement), LIF
KO DMEM, FCS, LIF
MEF:EEF feeders (1:1) SNL feeders MEF feeders Feeder-free MEF feeders
Pluripotency markers
expressed a
ALP, NANOG, OCT4,
KLF4, SSEA1, SSEA4,
TRA1-60, TRA1-81
ALP, OCT4, SOX2, NANOG,
REX1, LIN28, DNMT3B,
SSEA1, SSEA4, TRA1-60
ALP, OCT4, SOX2,
NANOG, STAT3,
SSEA1, SSEA4
ALP, OCT4, SOX2,
NANOG, REX1, LIN28,
DNMT3B, SSEA1
ALP, NANOG, OCT4,
TERT, REX1, SSEA4,
TRA1-60, TRA1-81
Differentiation potential
In vitro Not tested Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
In vivo Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
Ectoderm, mesoderm,
endoderm
Not tested
Clinically relevant
lineages generated
Keratinocytes (19) Not reported Not reported Functional
motor-neurons
Not reported
aGene symbols are shown according to current HGNC guidelines (http://www.genenames.org/about/guidelines#criteria).
MMLV, Moloney murine leukemia virus; FBS, fetal bovine serum; LIF, leukemia inhibitory factor; bFGF, basic fibroblast growth factor; MEF, mouse embryonic fibroblasts; EEF, equine
embryonic fibroblasts; ITS, insulin–transferrin–selenium; EGF, epidermal growth factor.
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expression of the reprogrammingDNAsequences in these cells led
to loss of pluripotency and rapid differentiation, indicating that
re-activated expression of endogenous pluripotency genes during
reprogramming was not sufficient to sustain the pluripotent state.
Consistent with this observation, all other iPSC lines reported
to date show clear but variable expression of the reprogramming
genes, similar to observations from other domestic species (9, 11,
12). Given that silencing of the exogenous reprogramming genes is
in general considered a hallmark of faithful reprogramming (20),
the above findings bring into question whether equine iPSC lines
reported so far are fully reprogrammed or they represent instead a
partially reprogrammed cell type; potential implications of this, if
any, in relation to a possible clinical application of these cells need
to be established.
POTENTIAL OF iPSCs IN
EQUINE BIOMEDICINE
Induced pluripotent stem cells offer truly unprecedented potential
both as a source of therapeutic cells and as a tool for in vitro
disease modeling and drug discovery. The tissue regeneration
potential of iPSCs has been demonstrated using different animal
models of disease, including spinal cord injury (21), Parkinson
(22), and retinal degeneration (23). Notably, the first human clin-
ical trials using autologous iPSCs are already underway in Japan
to treat age-related macular degeneration, and significant work
is being carried out toward other eventual clinical applications.
A particularly exciting possibility in this regard involves the use
of iPSCs in combination with novel gene editing technologies as
a new strategy for gene therapy; although a long-term clinical
prospect, success using this combined approach has been reported
in experimental rodent models, including sickle cell anemia (24)
and limb-girdle muscular dystrophy (25).
Very early steps have been given to test the clinical efficacy
and safety of PSCs in the horse. Guest et al. (5) injected equine
ESC-like cells into damaged tendon of live horses and showed
superior cell survival and migration to damaged tissue compared
to transplanted bone marrow-derivedMSCs. Amore recent study
showed intradermal injection of equine allogeneic iPSCs to be
relatively well-tolerated and without noticeable long-term effects
(26). These reports are encouraging and further studies will need
to test the potential of iPSCs in relation to specific disorders in
the horse. Clinically, equine iPSCs may be most useful in the first
instance as an alternative to current MSC-based musculoskeletal
therapies. In this regard, significant benefits can be gained from
progress made with humans for which different protocols are
already available to derive MSC-like cells from iPSCs (27–29),
moreover, the potential of such cells for tissue regeneration has
been clearly demonstrated using mouse models of limb ischemia
(27, 29). Although, in principle, iPSCs could be derived from
any equine patient, the time required for the generation and pre-
clinically testing of such cells will prevent their therapeutic use
early during the disease course, making autologous application
a suitable option only for some non-acute disorders. Indeed,
equine iPSCswill have greatest clinical potential as an off-the-shelf
source of therapeutic, in vitro-producedmesenchymal precursors,
a possibility that holds particular attractive at a moment when
allogeneic cell therapies are being increasingly considered in the
horse.Off-the-shelf iPSC-derived cells could have applications not
only in musculoskeletal repair but also for other common con-
ditions, including external wounds, ischemic/inflammatory pro-
cesses such as laminitis or gastro-intestinal disease, autoimmune
disorders, and even neuro-regeneration (16, 19).
Despite their enormous clinical promise, given present con-
cerns about overall clinical safety (discussed below), disease mod-
eling is seen as the application for which iPSCs, in general, will be
most useful in the short term. In that regard, the differentiation
of human patient-derived iPSCs into functional cells capable of
recapitulating specific disease phenotypes has provided a truly
unmatched tool for studying diseases in vitro. Disorders success-
fully modeled in this way include neurological, cardiovascular,
hematological and metabolic (30); such studies have unraveled
novel molecular mechanisms of disease as well as led to identifica-
tion of promising therapeutic targets. Most notably, elegant stud-
ies [reviewed in Ref. (31)] with human iPSC-derived cardiomy-
ocytes and neurons have elucidated novel genetic mechanisms in
the pathogenesis of long-QT syndrome and familial dysautono-
mia, respectively. Moreover, using neurons from patients with
familial dysautonomia or Rett syndrome led to the identification
of novel therapeutic compounds that are now being used in early-
stage clinical trials (31).
A similar potential for in vitro modeling of disease as well as
normal tissue development is held by equine iPSCs. This includes
the possibility, using appropriate iPSC-derived cell types, of study-
ing the effects of different genetic backgrounds or horse breeds
on disease resistance and the responses to specific therapies.
This information could be extremely valuable for developing new
therapies or improving current approaches for equine patients.
The limited knowledge, both basic and applied, on developmen-
tal/stem cell biology and molecular aspects of disease in the
horse will certainly pose significant challenges to such applica-
tion. These include the need to establish robust differentiation
protocols to produce cells phenotypically equivalent to the cell
type(s) under study, and to appropriately identify and measure
phenotypes that relate to the diseases of interest, which may be
species specific. Diseases for which a phenotype is most likely
to be obtained in vitro and for which iPSCs may be most use-
ful are early-onset, cell-autonomous defects caused by known,
high penetrance mutations. Several monogenic diseases with a
defined causal mutation have been identified in horses (http://
omia.angis.org.au). Some, such as hyperkalemic periodic paraly-
sis and exertional rhabdomyolysis, have a relatively high, breed-
specific prevalence and could be readily targeted. In that case,
the phenotype of myocytes derived from iPSCs from affected and
healthy animals would be compared to understand the cellular
mechanisms underlying the disease(s) and establish the responses
to potential therapeutic agents; alternatively, myocytes could be
derived from healthy iPSCs in which the causal gene mutation
would have been previously induced and would be compared to
myocytes generated from non-mutated iPSCs (30). Advances in
sequencing of the equine genome, together with the development
over the past few years of readily available technologies for pre-
cise genome editing will significantly facilitate such undertakings
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toward making real therapeutic progress in relation to those and
many other equine diseases.
CHALLENGES FOR THE APPLICATION OF
iPSCs IN EQUINE BIOMEDICINE
In spite of their enormous potential, several challenges related to
clinical safety will first need to be overcome before a therapeu-
tic use of equine iPSCs can be considered. The most important
concern at present is the possibility of tumor formation following
transplantation of iPSCs into patients. The capacity to generate
a wide variety of unwanted tissue types after transplantation,
including malignant tumors derives from the inherent develop-
ment plasticity of all pluripotent cells. In addition, the repro-
gramming process itself together with the repeated passaging of
the reprogrammed cells in culture can lead to significant genetic
and epigenetic instability and an increased propensity for tumor
formation (32). Another very important consideration is that
iPSCs are typically generated by inducing the expression of gene
sequences (Oct4, Sox2, Klf4, and c-Myc) which by themselves
can be tumorigenic. As already pointed out, reprogramming is
most efficiently achieved by the use of viral vectors carrying the
reprogramming genes that become permanently integrated into
the cell’s genome, resulting in reprogrammed cells that harbor
foreign, potentially tumorigenic DNA. In addition, the continued
expression of these genes can impinge on the ability of the iPSCs
to later differentiate properly into adult cell types (consistent with
the notion that silencing of the reprogramming genes is a hallmark
of successful reprogramming), thus, reducing their clinical appli-
cability (21). Efforts to circumvent these issues have resulted in the
development of several non-integrating expression systems (33,
34), which can now be used routinely to generate human iPSCs
with reasonable efficiency. Based on results (13) using a piggy-
Bac transposon system to reprogram equine fibroblasts and on
several reports in other domestic species [reviewed in Ref. (35)],
it is likely that significant optimization of reprogramming and
culture conditions will be necessary to efficiently derive robust
equine iPSCs using available non-integrating expression systems.
Such efforts will be essential for any eventual clinical application
of these cells. In addition, thorough molecular and functional
characterization and testing of individual iPSC lines intended for
clinical use will be mandatory to completely rule out genetic or
phenotypic traits indicative of tumorigenic capacity. Despite all
these challenges, studies in other species have already reported
the successful transplantation of iPSC-derived cells without any
resulting tumorigenicity or immunogenicity (21).
Related to the point above, a significant challenge toward an
eventual clinical use of equine iPSCs will be the development of
robust protocols for unidirectional and efficient differentiation
to specific mature and functional cell types. Significant progress
has already been made in human, rodent, and even pig (30, 36),
iPSCs from which species can now be differentiated into cells
resembling, with variable fidelity, many different body cell types;
a remaining limitation in that regard is that iPSC-derived cells
often present immature, fetal-like phenotypes that may not be
suitable for tissue transplantation, requiring future refinement of
cell differentiation protocols. In the case of the horse, an additional
limitation is the relatively lack of knowledge of normal cellular
and molecular mechanisms of development, the recapitulation of
which in vitro may be required to robustly produce cell lineages
of interest. Despite this, progress has already been made with the
successful generation for the first time of functional cells from
iPSCs, namely 1) functional motor-neurons (16) and 2) cells that
both expressed keratinocyte markers and were able to epithelize
wounds in vitro (19). These achievements have provide important
proof of concept of the biomedical potential of equine iPSCs and
should encourage further exploratory studies.
The immunogenicity of transplanted iPSC derivatives will also
need to be addressed. Although not tested in the horse, studies
in mice and primates (37, 38) have shown that transplantation of
autologous iPSC-derived cells inducesminimal immune response,
in contrast to the substantial activation and infiltration of immune
cells leading to reduced survival of transplanted allografts. In that
regard, although encouraging, the recent report that intradermal
injection of allogeneic equine iPSCs produced only a moderate
immune response at the site of injection needs to be interpreted
with caution as the long-term fate of the injected cells was not
established (26). As a clinical use of iPSCs in the future is more
likely to occur in an allogeneic context, specific strategies to
induce immune tolerancemay need to be developed. The creation
of human iPSC haplobanks from individuals homozygous at the
major HLA antigens has been proposed as a route to provide
immuno-compatible cells for a large proportion of the human
population (39); whether such an ambitious approach would be
necessary, and feasible, in the horse remains to be seen.
Finally, in addition to safety considerations, the allogeneic use
of equine iPSC derivatives would likely come under regulatory
scrutiny, including Good Manufacture Practice guidelines for
their derivation, storage, and application in patients. While steps
already being given in the human field could be followed, the
implementation of such measures would require a much better
understanding of the nature of equine iPSCs and a significant
optimization and validation of the procedures currently used for
their generation, culture, and differentiation.
In conclusion, although significant challenges in relation to
an eventual safe therapeutic application of iPSCs remain ahead,
through their demonstrated clinical and in vitromodeling poten-
tial, iPSCs provides an opportunity tomake unprecedented strides
toward understanding and treating a variety of equine diseases.
Such perspectives should stimulate work by the equine scientific
community toward a better understanding of the nature and
biomedical potential of these cells.
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